- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging PET Imaging Agent Gets FDA’s Breakthrough Therapy Designation for Cardiac Amyloidosis
Reportedly the only imaging agent to garner a breakthrough therapy designation for cardiac amyloidosis, 124I-evuzamitide has demonstrated robust sensitivity for the condition as well as a favorable safety profile.
The Food and Drug Administration (FDA) has granted a breakthrough therapy designation for use of the positron emission tomography (PET) imaging agent 124I-evuzamitide (AT-01) for patients with suspected or known cardiac amyloidosis.
The first non-invasive pan-amyloid PET agent designed for systemic amyloidosis, 124I-evuzamitide has reportedly demonstrated effectiveness in detecting multiple types of amyloid deposits in the liver, kidney, and heart, according to Attralus, the developer of 124I-evuzamitide.1
The first non-invasive pan-amyloid PET agent designed for systemic amyloidosis, 124I-evuzamitide recently garnered a breakthrough therapy designation from the FDA for use in patients with suspected or known cardiac amyloidosis. (Images courtesy of Attralus.)
In a recent study evaluating the use of 124I-evuzamitide for 50 patients with systemic amyloidosis, researchers noted a 96.2 percent cardiac-associated sensitivity rate and one drug-related adverse event.2
Emphasizing that 124I-evuzamitide is the only diagnostic imaging agent to garner a breakthrough therapy designation for cardiac amyloidosis, Attralus says the FDA’s decision was based on multiple studies evaluating use of the radiotracer in patients with cardiac amyloidosis.1
“We are highly encouraged by FDA’s decision to grant Breakthrough Therapy Designation to 124I-evuzamitide (AT-01), recognizing its potential as an innovative diagnostic agent for patients with systemic amyloidosis” said Gregory Bell, M.D., the chief medical officer at Attralus. “There are no FDA approved diagnostic imaging agents for cardiac amyloidosis. The diagnosis of cardiac amyloidosis is a challenging and time-consuming process for patients, with many going years without an accurate diagnosis, and losing critical time in the process.”
Attralus added that 124I-evuzamitide (AT-01) will be the subject of a phase 3 study of patients with suspected cardiac amyloidosis that is slated to begin in 2025.
References
1. Attralus. Attralus receives breakthrough therapy designation for its pan-amyloid diagnostic PET imaging candidate 124I-evuzamitide (AT-01) for cardiac amyloidosis. Globe Newswire. Available at: https://www.globenewswire.com/news-release/2024/08/05/2924179/0/en/Attralus-Receives-Breakthrough-Therapy-Designation-for-its-Pan-Amyloid-Diagnostic-PET-Imaging-Candidate-124I-evuzamitide-AT-01-for-Cardiac-Amyloidosis.html . Published August 5, 2024. Accessed August 5, 2024.
2. Wall JS, Martin EB, Lands R, et al. Cardiac amyloid detection by PET/CT imaging of iodine (124I) evuzamitide (124I-p5+14): a phase 1/2 study. JACC Cardiovasc Imaging. 2023;16(11):1433-1448.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
